New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 29, 2014
07:48 EDTJAZZJazz Pharmaceuticals price target raised to $177 from $171 at Leerink
Leerink raised its price target for Jazz Pharmaceuticals shares to $177 citing an improved outlook for defibrotide. The firm keeps an Outperform rating on the stock.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
11:59 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals/Generics Analyst Gerberry discusses the strengths and weaknesses of TEVA’s preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and the perspectives on recent updates in the Jazz Pharmaceuticals' Xyrem patent case on an Analyst/Industry conference call to be held on July 27 at 11 am.
July 20, 2015
10:26 EDTJAZZLeerink's specialty pharma/generics analyst has analyst/industry conference call
Specialty Pharmaceuticals / Generics Analyst Gerberry, along with MEDACorp Specialists Michael Belliveau, PhD and Shashank Upadhye, JD, discuss the strengths and weaknesses of TEVA's preliminary responses to the IPR challenge on Copaxone 40mg, the likely outcomes for the Copaxone 40mg patent challenge and perspectives on recent updates in the JAZZ Xyrem patent case on an Analyst/Industry conference call to be held on July 22 at 2 pm.
July 17, 2015
08:38 EDTJAZZLeerink puts 25% odds on Teva, Mylan deal within 12 months
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use